



Pablo Legorreta is the founder, CEO and Chairman of Royalty Pharma. Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company's collaborations span the entire research and development ecosystem, from academic institutions, research hospitals, and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than \$20 billion of capital to advance innovation in the biopharmaceutical industry.

Mr. Legorreta is a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. He is also a co-founder of ProKidney, a biotech company developing pioneering therapies that have the potential to change the lives of people with chronic kidney disease.

Mr. Legorreta is also the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (US), The American Austrian Foundation/Open Medical Institute and Park Avenue Armory.

Prior to founding Royalty Pharma, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York.